Spots Global Cancer Trial Database for neosar
Every month we try and update this database with for neosar cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
Adoptive Therapy Using Antigen-Specific CD4 T-Cells | NCT02210104 | Melanoma Sarcoma | Ipilimumab Cyclophosphamid... CD4+ T cells | 18 Years - | M.D. Anderson Cancer Center | |
Molecular Triaging of Newly Diagnosed Breast Cancer | NCT01159236 | Breast Cancer | Paclitaxel Fluorouracil Doxorubicin Epirubicin Cyclophosphamid... Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
Randomized Double Cord Blood Transplant Study | NCT00067002 | Leukemia, Lymph... Leukemia, Myelo... Leukemia, Myelo... Lymphoma, Non-H... | Expanded alloge... One Unmanipulat... Rituxan Melphalan Thiotepa Fludarabine Cyclophosphamid... Mesna Total body irra... | 1 Month - 80 Years | M.D. Anderson Cancer Center | |
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT00941928 | Leukemia Pediatric Cance... | Epratuzumab Fludarabine Cyclophosphamid... Mesna Infusion of NK ... Interleukin-2 | - | M.D. Anderson Cancer Center | |
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
Treatment of Tumors of the Choroid Plexus Epithelium | NCT00500890 | Choroid Plexus ... | Carboplatin Cyclophosphamid... Etoposide Vincristine Radiation Thera... | - | M.D. Anderson Cancer Center | |
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
Safety and Efficacy of Campath in Nonmyeloablative Transplantation | NCT00038844 | Lymphoma Leukemia | Campath-1 H (Al... Fludarabine Cyclophosphamid... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
Primary Breast Cancer Occurring Concomitant With Pregnancy | NCT00510367 | Breast Cancer Pregnancy | 5-Fluorouracil Cyclophosphamid... Doxorubicin | - | M.D. Anderson Cancer Center | |
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia | NCT00446173 | Leukemia | Busulfan Cyclophosphamid... G-CSF GM-CSF | 21 Years - 65 Years | M.D. Anderson Cancer Center | |
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01082939 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Alemtuzumab Rituximab | - | M.D. Anderson Cancer Center | |
Autologous Transplantation for Chronic Myelogenous Leukemia | NCT01003054 | Chronic Myeloge... | Busulfan Cyclophosphamid... Imatinib Mesyla... Autologous Stem... | - 70 Years | M.D. Anderson Cancer Center | |
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) | NCT01253460 | Leukemia | Cyclophosphamid... Rituximab Sapacitabine | 18 Years - | M.D. Anderson Cancer Center | |
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | NCT00048737 | Lymphoma Leukemia | Zevalin Radioim... Rituximab Fludarabine Cyclophosphamid... Allogeneic Stem... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | NCT00002844 | Leukemia | Cyclophosphamid... Allogeneic Bone... Autologous Bone... Total Body Irra... | 16 Years - 65 Years | M.D. Anderson Cancer Center | |
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma | NCT00787527 | Lymphoma | Zolinza (vorino... Cyclophosphamid... Doxorubicin Vincristine Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | NCT00857389 | Stem Cell Trans... Leukemia Lymphoma | Thiotepa Clofarabine Busulfan Allogeneic Stem... Thymoglobulin (... G-CSF (Filgrast... Tacrolimus Methotrexate Cyclophosphamid... Mesna | - 60 Years | M.D. Anderson Cancer Center | |
Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | NCT00002844 | Leukemia | Cyclophosphamid... Allogeneic Bone... Autologous Bone... Total Body Irra... | 16 Years - 65 Years | M.D. Anderson Cancer Center | |
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma | NCT00698009 | Neuroblastoma | Fludarabine Cyclophosphamid... Natural Killer ... Mesna Interleukin-2 | - | M.D. Anderson Cancer Center | |
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer | NCT00038402 | Breast Cancer | Herceptin Taxol Fluorouracil Cytoxan Epirubicin | - | M.D. Anderson Cancer Center | |
Safety and Efficacy of Campath in Nonmyeloablative Transplantation | NCT00038844 | Lymphoma Leukemia | Campath-1 H (Al... Fludarabine Cyclophosphamid... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
Adoptive Therapy Using Antigen-Specific CD4 T-Cells | NCT02210104 | Melanoma Sarcoma | Ipilimumab Cyclophosphamid... CD4+ T cells | 18 Years - | M.D. Anderson Cancer Center | |
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab | NCT00958256 | Mantle Cell Lym... Lymphoma | Bortezomib Rituximab Cyclophosphamid... Mesna G-CSF | 18 Years - 85 Years | M.D. Anderson Cancer Center | |
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer | NCT00429182 | Breast Cancer Metastatic Brea... Invasive Breast... | Carboplatin Cyclophosphamid... Thiotepa Stem Cell Trans... | 18 Years - 55 Years | M.D. Anderson Cancer Center | |
Autologous Transplantation for Chronic Myelogenous Leukemia | NCT01003054 | Chronic Myeloge... | Busulfan Cyclophosphamid... Imatinib Mesyla... Autologous Stem... | - 70 Years | M.D. Anderson Cancer Center | |
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma | NCT01039025 | Myeloma | Topotecan Cyclophosphamid... Melphalan Peripheral Bloo... | - 70 Years | M.D. Anderson Cancer Center | |
Adoptive Therapy Using Antigen-Specific CD4 T-Cells | NCT02210104 | Melanoma Sarcoma | Ipilimumab Cyclophosphamid... CD4+ T cells | 18 Years - | M.D. Anderson Cancer Center | |
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger | NCT00290498 | Lymphoma | Rituximab Cyclophosphamid... Doxorubicin Vincristine Dexamethasone Methotrexate Cytarabine Prednisone | 16 Years - 60 Years | M.D. Anderson Cancer Center | |
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
Safety and Efficacy of Campath in Nonmyeloablative Transplantation | NCT00038844 | Lymphoma Leukemia | Campath-1 H (Al... Fludarabine Cyclophosphamid... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
Non-Myeloablative Allogeneic Stem Cell Transplantation | NCT00525876 | Lymphoma | Cyclophosphamid... Fludarabine Rituximab Alemtuzumab Allogeneic Stem... | - 70 Years | M.D. Anderson Cancer Center | |
Treatment of Tumors of the Choroid Plexus Epithelium | NCT00500890 | Choroid Plexus ... | Carboplatin Cyclophosphamid... Etoposide Vincristine Radiation Thera... | - | M.D. Anderson Cancer Center | |
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
Molecular Triaging of Newly Diagnosed Breast Cancer | NCT01159236 | Breast Cancer | Paclitaxel Fluorouracil Doxorubicin Epirubicin Cyclophosphamid... Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 | NCT01593020 | Breast Cancer | Paclitaxel Eribulin 5-Fluorouracil Epirubicin Cyclophosphamid... Doxorubicin | 18 Years - | M.D. Anderson Cancer Center | |
Primary Breast Cancer Occurring Concomitant With Pregnancy | NCT00510367 | Breast Cancer Pregnancy | 5-Fluorouracil Cyclophosphamid... Doxorubicin | - | M.D. Anderson Cancer Center | |
Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells | NCT01362452 | Leukemia Lymphoma | T-Cell Infusion Cord Blood Infu... | 1 Year - 75 Years | M.D. Anderson Cancer Center | |
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma | NCT00338377 | Melanoma | Dendritic Cell ... Cyclophosphamid... Fludarabine T-Cells Interleukin-2 Mesna Intrathecal T-C... Intrathecal Int... | 12 Years - | M.D. Anderson Cancer Center | |
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | NCT02419469 | Leukemia Precursor-B Acu... Lymphoblastic L... Lymphoma | Cytarabine Daunorubicin Vincristine Prednisone PEG asparaginas... Ofatumumab Rituximab Methotrexate Cyclophosphamid... Mercaptopurine Doxorubicin Dexamethasone a... Thioguanine | 12 Years - 30 Years | M.D. Anderson Cancer Center | |
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab | NCT00667329 | Lymphoma | 2CdA Cyclophosphamid... Rituximab | - | M.D. Anderson Cancer Center | |
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab | NCT00667329 | Lymphoma | 2CdA Cyclophosphamid... Rituximab | - | M.D. Anderson Cancer Center | |
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | NCT00857389 | Stem Cell Trans... Leukemia Lymphoma | Thiotepa Clofarabine Busulfan Allogeneic Stem... Thymoglobulin (... G-CSF (Filgrast... Tacrolimus Methotrexate Cyclophosphamid... Mesna | - 60 Years | M.D. Anderson Cancer Center | |
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01082939 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Alemtuzumab Rituximab | - | M.D. Anderson Cancer Center | |
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | NCT02419469 | Leukemia Precursor-B Acu... Lymphoblastic L... Lymphoma | Cytarabine Daunorubicin Vincristine Prednisone PEG asparaginas... Ofatumumab Rituximab Methotrexate Cyclophosphamid... Mercaptopurine Doxorubicin Dexamethasone a... Thioguanine | 12 Years - 30 Years | M.D. Anderson Cancer Center | |
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer | NCT01036087 | Breast Cancer | Panitumumab Nab-paclitaxel Carboplatin 5-Fluorouracil Epirubicin Cyclophosphamid... | 18 Years - | M.D. Anderson Cancer Center |